EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma

Ji Liu, Zhekang Liu, Deming Xu, Tao Zhou, Ang Li, Jiali Hu, Hong Li, Wenjie Li, Zengqing Wang, Zhiping Yu, Linxiang Zeng

International Journal of General Medicine · 2024-12 · Volume 17 · 6465-6478

DOI: 10.2147/ijgm.s501401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of General Medicine, 2024-12. Verfasst von Ji Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Rep…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Biomarkeradvanced lung adenocarcinomaepidermal growth factor receptorlipoprotein (a)progression-free survival

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
  • Rheumatology and Immunology department, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
  • Department of Geriatrics, the First People's Hospital of Jiashan County, Jiaxing, Zhejiang Province, People's Republic of China.

Zitieren

APA

Liu, J., Liu, Z., Xu, D., Zhou, T., Li, A., Hu, J., Li, H., Li, W., Wang, Z., Yu, Z., & Zeng, L. (2024). Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma. International Journal of General Medicine, Volume 17, 6465-6478. https://doi.org/10.2147/ijgm.s501401

Vancouver

Liu J, Liu Z, Xu D, Zhou T, Li A, Hu J, et al. Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma. International Journal of General Medicine. 2024;Volume 17:6465-6478. doi:10.2147/ijgm.s501401

BibTeX
@article{Liu2024,
  author = {Liu, Ji and Liu, Zhekang and Xu, Deming and Zhou, Tao and Li, Ang and Hu, Jiali and Li, Hong and Li, Wenjie and Wang, Zengqing and Yu, Zhiping and Zeng, Linxiang},
  title = {Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma},
  journal = {International Journal of General Medicine},
  year = {2024},
  volume = {Volume 17},
  pages = {6465--6478},
  doi = {10.2147/ijgm.s501401}
}
Kostenlos starten →